Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study

Azam, Ayesha S; Tsang, Yee‐Wah; Thirlwall, Jenny; Kimani, Peter K; Sah, Shatrughan; Gopalakrishnan, Kishore; Boyd, Clinton; Loughrey, Maurice B; Kelly, Paul J; Boyle, David P; Salto‐Tellez, Manuel; Clark, David; Ellis, Ian O; Ilyas, Mohammad; Rakha, Emad; Bickers, Adam; Roberts, Ian S D; Soares, Maria F; Neil, Desley A H; Takyi, Abi; Raveendran, Sinthuri; Hero, Emily; Evans, Harriet; Osman, Rania; Fatima, Khunsha; Hughes, Rhian W; McIntosh, Stuart A; Moran, Gordon W; Ortiz‐Fernandez‐Sordo, Jacobo; Rajpoot, Nasir M; Storey, Ben; Ahmed, Imtiaz; Dunn, Janet A; Hiller, Louise; Snead, David R J

doi:10.1111/his.15129

All Outputs (3)

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers (2024)
Journal Article
Lashen, A., Algethami, M., Alqahtani, S., Shoqafi, A., Sheha, A., Jeyapalan, J. N., …Madhusudan, S. (2024). The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 25(7), Article 4060. https://doi.org/10.3390/ijms25074060

Cyclin-dependent kinases (CDK2, CDK4, CDK6), cyclin D1, cyclin E1 and phosphorylated retinoblastoma (pRB1) are key regulators of the G1/S cell cycle checkpoint and may influence platinum response in ovarian cancers. CDK2/4/6 inhibitors are emerging t... Read More about The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.

The characteristics and prognostic significance of histone H1 expression in breast cancer (2024)
Journal Article
Lashen, A. G., Almalki, N., Toss, M., Mirza, S., Malki, M. I., Rutland, C. S., …Rakha, E. A. (in press). The characteristics and prognostic significance of histone H1 expression in breast cancer. Pathology,

Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study (2024)
Journal Article
Azam, A. S., Tsang, Y., Thirlwall, J., Kimani, P. K., Sah, S., Gopalakrishnan, K., …Snead, D. R. J. (2024). Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study. Histopathology, 84(5), 847-862. https://doi.org/10.1111/his.15129

Aims: To conduct a definitive multicentre comparison of digital pathology (DP) with light microscopy (LM) for reporting histopathology slides including breast and bowel cancer screening samples. Methods: A total of 2024 cases (608 breast, 607 GI, 6... Read More about Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study.